Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2020 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic.
Vucenik I, Shamsuddin AM. Vucenik I, et al. J Nutr. 2003 Nov;133(11 Suppl 1):3778S-3784S. doi: 10.1093/jn/133.11.3778S. J Nutr. 2003. PMID: 14608114 Review.
IP6 plus inositol enhances the anticancer effect of conventional chemotherapy, controls cancer metastases, and improves the quality of life, as shown in a pilot clinical trial. The data strongly argue for the use of IP6 plus inositol in o
IP6 plus inositol enhances the anticancer effect of conventional chemotherapy, controls cancer metastases, and improves
Suramin and NF449 are IP5K inhibitors that disrupt inositol hexakisphosphate-mediated regulation of cullin-RING ligase and sensitize cancer cells to MLN4924/pevonedistat.
Zhang X, Shi S, Su Y, Yang X, He S, Yang X, Wu J, Zhang J, Rao F. Zhang X, et al. J Biol Chem. 2020 Jul 24;295(30):10281-10292. doi: 10.1074/jbc.RA120.014375. Epub 2020 Jun 3. J Biol Chem. 2020. PMID: 32493769 Free PMC article.
Inositol hexakisphosphate (IP(6)) is an abundant metabolite synthesized from inositol 1,3,4,5,6-pentakisphosphate (IP(5)) by the single IP(5) 2-kinase (IP5K). ...IP5K is a potential mechanistic target of suramin, accounting for suramin's therapeutic effects..
Inositol hexakisphosphate (IP(6)) is an abundant metabolite synthesized from inositol 1,3,4,5,6-pentakisphosphate (IP(5)) by t